Roche gets FDA nod for Tecentriq plus chemotherapy to treat metastatic NSCLC

This article was originally published here

The approval has been granted for Tecentriq in combination with Abraxane (paclitaxel protein-bound; nab-paclitaxel) and carboplatin for the first-line treatment of adults with metastatic NSCLC with no EGFR

The post Roche gets FDA nod for Tecentriq plus chemotherapy to treat metastatic NSCLC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply